Compare Cenovus Energy Inc (CVE) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cenovus Energy Inc vs McKesson Corporation — how do they compare? Cenovus Energy Inc trades at $31.38 (market cap $57.90B), while McKesson Corporation trades at $930 (market cap $108.46B). The key difference: McKesson Corporation is the larger of the two by market cap, and Cenovus Energy Inc pays the higher dividend (1.97%). Which is the better fit depends on your goals — on Pluang, investors hold Cenovus Energy Inc for 46 Days and McKesson Corporation for 74 Days on average.
| CVE | MCK | |
|---|---|---|
Market Cap | $57.90B | $108.46B |
Volume | 7,863,588 | 712,607 |
Sector | Energy | Health |
52-Week High | $33.92 | $995.69 |
52-Week Low | $15.85 | $725.17 |
Typical Hold Time | 46 Days | 74 Days |
Enterprise Value | $63.84B | $115.00B |
Dividend Yield | 1.97% | 0.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cenovus Energy (CVE) trades at $30.63, down 1.95% on the day, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with a P/E of 12.14, EV/EBITDA of 6.03, and robust profitability metrics including 20.96% ROE. Recent analyst coverage shows 40.74% buy ratings, while technical indicators point to support near $30 with resistance at $31-32 levels. Cash flow trends indicate operational strength with $8.23B from operations in 2025.
CVE presents a mixed outlook with attractive valuation metrics and strong profitability offset by bearish technical signals. The company's projected 2026 revenue growth to $58B and net income of $6.7B suggests upside potential, though energy sector volatility and recent price weakness near key support levels warrant caution. Analyst consensus leans positive with limited sell-side coverage.
McKesson Corporation (MCK) trades at $910.33, down 1.23% today, but maintains strong analyst support with 80.65% buy ratings and a $956.43 consensus price target. The stock shows bullish technical momentum with recent earnings beats and a major distribution agreement extension with CVS Health through 2032. Revenue growth has accelerated from $264B in 2022 to $359B in 2025, though net margins remain thin at 1.12%.
MCK presents a compelling growth story with consistent earnings outperformance and strategic partnerships driving long-term visibility. However, investors face risks from margin compression, drug pricing pressures, and high leverage with negative shareholder equity. The current valuation at 24.42x P/E appears reasonable given the company's market leadership and oncology growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cenovus Energy Inc
Cenovus Energy is an integrated oil company, focused on creating value through the development of its oil sands assets. The company also engages in production of conventional crude oil, natural gas liquids, and natural gas in Alberta, Canada, with refining operations in the U.S. Net upstream production averaged 472 thousand barrels of oil equivalent per day in 2020, and the company estimates that it holds 6.7 billion boe of proven and probable reserves.
Read more on CVE →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
